National- and state-level impact and cost-effectiveness of nonavalent HPV vaccination in the United States
David P. Durham(Yale University), Alison P. Galvani(Yale University), Laura Skrip(London School of Hygiene & Tropical Medicine), Chris T. Bauch(University of Waterloo), Martial L. Ndeffo-Mbah(Texas A&M University), Forrest K. Jones(Yale University)
Cited by 62
Related Papers
Global burden of HIV, viral hepatitis, and tuberculosis in prisoners and detainees
|The Lancet|2016|648
Coupled disease–behavior dynamics on complex networks: A review
|Physics of Life Reviews|2015|547
A review and agenda for integrated disease models including social and behavioural factors
|Nature Human Behaviour|2021|227
Comparative cost-effectiveness of SARS-CoV-2 testing strategies in the USA: a modelling study
|The Lancet Public Health|2021|169
Community engagement in outbreak response: lessons from the 2014–2016 Ebola outbreak in Sierra Leone
|BMJ Global Health|2020|102